GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Chengdu Olymvax Biopharmaceuticals 688319.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

27.44

-2.66%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Chengdu Olymvax Biopharmaceuticals

Its shares trade on Shanghai under the ticker 688319.SS. It has been listed since 8 June 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥704.2m and net income of CN¥22.2m. At that date it held total assets of CN¥2.02bn and shareholders' equity of CN¥903.7m.

Chengdu Olymvax Biopharmaceuticals, Inc. engages in the research and development, manufacture, and sale of human-use vaccines. The company is headquartered in Chengdu, Sichuan. The company went IPO on 2021-06-08. The firm's products mainly include adsorbed tetanus vaccine, Hib conjugate vaccine and tetanus toxoid concentrate stock solution. The firm's main customers are center for disease control and prevention (CDC) customers.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
8 Jun 2021
Employees
440
Website
olymvax.com ↗

Leadership

Pay as last reported

  • Mr. Shaowen FanChairman of the Board, General Manager
  • Mr. Yong TanChief Financial Officer
  • Mr. Hengjun MaExecutive Deputy General Manager
  • Mr. Wei WuSecretary of the Board, Assistant General Manager

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Chengdu Olymvax Biopharmaceuticals employs 440 full-time employees in biotechnology research.
  • The company's main products include adsorbed tetanus vaccine and Hib conjugate vaccine.
  • Chengdu, Sichuan serves as the headquarters for vaccine research and development.

Weaknesses

  • The company's main customers are limited to CDC centers for disease control.
  • Chengdu Olymvax Biopharmaceuticals has no international presence beyond China.
  • The firm's product range is restricted to specific vaccine types.

Opportunities

  • The growing demand for vaccines in China presents expansion opportunities.
  • Chengdu's biotechnology sector offers potential for collaboration and innovation.
  • Increasing government funding for health care in Sichuan province supports growth.

Threats

  • Dependence on CDC customers poses a risk if government funding decreases.
  • Competition from other Chinese biotechnology firms in vaccine development.
  • Regulatory changes in China could impact vaccine manufacturing processes.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.